2021
Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticCombined Modality TherapyFemaleHumansLiver NeoplasmsMaleMiddle AgedRetrospective StudiesTreatment OutcomeConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient groupManagement of Refractory Ascites Due to Portal Hypertension: Current Status.
Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021, 298: 493-504. PMID: 33497318, DOI: 10.1148/radiol.2021201960.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRefractory ascitesPortal hypertensionTransjugular intrahepatic portosystemic shuntLarge-volume paracentesesCirrhotic portal hypertensionAvailable therapeutic optionsIntrahepatic portosystemic shuntStepwise management approachMost patientsMedical managementPoor prognosisPortosystemic shuntTherapeutic optionsTreatment optionsMultiple therapiesPatient outcomesAppropriate treatmentClinical experienceDrainage deviceSpecific patientAscitesHypertensionPatientsParacentesesPrognosis
2020
Is There a Role for Combination, Single-Session Selective Transarterial Embolization and Microwave Ablation for Large Renal Masses?
LaRussa S, Vanden Berg RW, Craig KM, Madoff DC, McClure TD. Is There a Role for Combination, Single-Session Selective Transarterial Embolization and Microwave Ablation for Large Renal Masses? CardioVascular And Interventional Radiology 2020, 43: 1468-1473. PMID: 32613266, DOI: 10.1007/s00270-020-02568-5.Peer-Reviewed Original ResearchConceptsLarge renal massTransarterial embolizationRenal tumorsRenal massesMicrowave ablationCharleston Comorbidity IndexLarge renal tumorsEvidence of recurrencePost-procedure complicationsAverage tumor sizeSelective transarterial embolizationSmall renal tumorsClear cell carcinomaMeeting inclusion criteriaPatient demographic informationGroin hematomaComorbidity indexResultsEleven patientsAverage BMICase seriesSuccessful ablationTumor sizeCell carcinomaMean ageRENAL score
2007
Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab
Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks ME. Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab. Journal Of Vascular And Interventional Radiology 2007, 18: 1588-1591. PMID: 18057297, DOI: 10.1016/j.jvir.2007.08.015.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabCetuximabColorectal NeoplasmsCombined Modality TherapyFemaleHumansLiver NeoplasmsMaleMicrospheresMiddle AgedRadiopharmaceuticalsTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsColorectal cancerTreatment experienceAdvanced unresectable colorectal cancerUnresectable colorectal cancerMetastatic colorectal cancerCohort of patientsYttrium-90 microspheresSystemic therapyBiologic agentsDrug AdministrationHepatic neoplasiaCetuximabPatientsCancerBevacizumabChemotherapyNeoplasiaTherapyCohortPhysiciansAdministration